Meine Merkliste  

3.047 Aktuelle Fachpublikationen von Future Medicine

mit folgenden Suchkriterien:

Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation

02.10.2015 | Jorge Duconge; Gualberto Ruaño, Pharmacogenomics, 2015

Pharmacogenomics Ahead of Print.


Pharmacogenomics in the treatment of lung cancer: an update

02.10.2015 | Daniela Morales-Espinosa; Silvia García-Román; Niki Karachaliou; Rafael Rosell, Pharmacogenomics, 2015

Significant advances have been made in the analysis of the human genome in the first decades of the 21st century and understanding of tumor biology has matured greatly. The identification of tumor-associated mutations and the pathways involved has led to the development of targeted anticancer ...


The DRD2/ANKK1 Taq1A polymorphism is associated with smoking cessation failure in patients with coronary heart disease

02.10.2015 | Otto Mayer Jr; Jitka Seidlerová; Václava Černá; Alena Kučerová; Jan Bruthans; Petra Vágovičová; Jiří Vaněk; Katarína ..., Personalized Medicine, 2015

Aim: We speculated whether DRD2 or CHRN subunit polymorphisms might be associated with the risk of smoking cessation failure in subjects after coronary heart disease (CHD) manifestation. Methods: A total of 964 patients with CHD, mean age 64.3 years (standard deviation [SD] 9.0), examined in the ...


Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment

02.10.2015 | Paulo Caleb Junior Lima Santos; Alexandre Costa Pereira, Pharmacogenomics, 2015

Familial hypercholesterolemia (FH) is an autosomal dominant disease mainly caused by mutations in the low-density lipoprotein receptor (LDLR) gene. FH patients present a wide variability regarding response to drugs and they are usually undertreated. Here, we review studies that evaluated the ...


Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese

02.10.2015 | Keiko Maekawa; Ryosuke Nakamura; Nahoko Kaniwa; Seiho Mizusawa; Aya Kitamoto; Takuya Kitamoto; Maho Ukaji; Yumiko Ma ..., Pharmacogenomics, 2015

Aim: To construct a simple, low-cost typing method for the surrogate marker of HLA-A*31:01, a risk factor for carbamazepine (CBZ) related Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Materials & methods: DNAs from Japanese SJS/TEN patients were used for genotyping and developing ...


Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation

30.09.2015 | Boyoon Choi; Myeong Gyu Kim; Nayoung Han; Therasa Kim; Eunhee Ji; Seonyang Park; In-Wha Kim; Jung Mi Oh, Pharmacogenomics, 2015

Aim: A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. Patients & methods: A PPK model was developed from 36 patients by a one-compartment ...


Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome

30.09.2015 | Eva Cuzzoni; Sara De Iudicibus; Raffaella Franca; Gabriele Stocco; Marianna Lucafò; Marco Pelin; Diego Favretto; And ..., Pharmacogenomics, 2015

Idiopathic nephrotic syndrome represents the most common type of primary glomerular disease in children: glucocorticoids (GCs) are the first-line therapy, even if considerable interindividual differences in thepir efficacy and side effects have been reported. Immunosuppressive and ...


Evaluation of the use of clinical decision support and online resources for pharmacogenomics education

30.09.2015 | Carolyn R Rohrer Vitek; Wayne T Nicholson; Cloann Schultz; Pedro J Caraballo, Pharmacogenomics, 2015

Aim: To assess impact and value of using clinical decision support (CDS) to drive providers toward online pharmacogenomics education. Materials & methods: CDS was used to target prescribers of codeine/tramadol, send an educational email, display alert/inbox and provide links to an online ...


Analyzing the potential for incorrect haplotype calls with different pharmacogenomic assays in different populations: a simulation based on 1000 Genomes data

30.09.2015 | Matthias Samwald; Kathrin Blagec; Sebastian Hofer; Robert R Freimuth, Pharmacogenomics, 2015

Aim: Many currently available pharmacogenomic assays and algorithms interrogate a set of ‘tag’ polymorphisms for inferring haplotypes. We wanted to test the accuracy of such haplotype inferences across different populations. Materials & methods: We simulated haplotype inferences made by existing ...


High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors

30.09.2015 | Sayed-Mohammad Hasheminasab; Mladen V Tzvetkov; Christian Schumann; Stefan Rüdiger; Stefan Boeck; Volker Heinemann; ..., Pharmacogenomics, 2015

Aim: To identify genomic variants in the EGFR pathway and in cytokines predisposing to skin toxicity from EGFR inhibitors. Patients & methods: In 126 patients with cancer and EGFR inhibitor therapy skin toxicity was quantified and EGFR and inflammatory pathway genes were analyzed by deep ...


Seite 1 von 305
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.